Societe des Industries Pharmaceutiques de Tunisie-S I PHA T (XTUN:SIPHA) 5-Year EBITDA Growth Rate: 0.00% (As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTUN:SIPHA Societe des Industries Pharmaceutiques de Tunisie-S I PHA T XTUN:SIPHA
12 GF Score
Price TND4.99
! 1 Warning Sign
View Full Analysis

What is Societe des Industries Pharmaceutiques de Tunisie-S I PHA T 5-Year EBITDA Growth Rate?

Societe des Industries Pharmaceutiques de Tunisie-S I PHA T XTUN:SIPHA 12 5-Year EBITDA Growth Rate is 0.00% as of . 20. GuruFocus rates XTUN:SIPHA with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's EBITDA per Share for the six months ended in . 20 was TND0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.


Societe des Industries Pharmaceutiques de Tunisie-S I PHA T  (XTUN:SIPHA) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.


Societe des Industries Pharmaceutiques de Tunisie-S I PHA T 5-Year EBITDA Growth Rate Related Terms


XTUN:SIPHA vs BIEI, PTXTQ, INQD: 5-Year EBITDA Growth Rate Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Societe des Industries Pharmaceutiques de Tunisie-S I PHA T 5-Year EBITDA Growth Rate vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's 5-Year EBITDA Growth Rate falls into.


XTUN:SIPHA
12GF Score
Societe des Industries Pharmaceutiques de Tunisie-S I PHA T XTUN:SIPHA
5-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Societe des Industries Pharmaceutiques de Tunisie-S I PHA T 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 5-Year EBITDA Growth Rate of 0.00% mean?
Societe des Industries Pharmaceutiques de Tunisie-S I PHA T (XTUN:SIPHA) has a 5-Year EBITDA Growth Rate of 0.00% as of . 20. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Societe des Industries Pharmaceutiques de Tunisie-S I PHA T and its competitors.
Is Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's 5-Year EBITDA Growth Rate too high?
Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's current 5-Year EBITDA Growth Rate is 0.00%. Overall, Societe des Industries Pharmaceutiques de Tunisie-S I PHA T has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's 5-Year EBITDA Growth Rate compare to BIEI and PTXTQ?
Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's 5-Year EBITDA Growth Rate of 0.00% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Drug Manufacturers company?
A good 5-Year EBITDA Growth Rate depends on the Drug Manufacturers industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Societe des Industries Pharmaceutiques de Tunisie-S I PHA T and its competitors. Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's current 5-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Societe des Industries Pharmaceutiques de Tunisie-S I PHA T stock overvalued right now?
Societe des Industries Pharmaceutiques de Tunisie-S I PHA T (XTUN:SIPHA) has a current 5-Year EBITDA Growth Rate of 0.00%. The current 5-Year EBITDA Growth Rate is 0.00%. Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Societe des Industries Pharmaceutiques de Tunisie-S I PHA T (XTUN:SIPHA), the current 5-Year EBITDA Growth Rate is 0.00% as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Societe des Industries Pharmaceutiques de Tunisie-S I PHA T Business Description

Address Fondouk Choucha, Ben Arous, TUN, 2013
Societe des Industries Pharmaceutiques de Tunisie-S I PHA T is a Tunisia-based company mainly engaged in manufacturing and distributing medicines and drugs. The company also has its own research and development process to develop generic drugs. It offers pharmaceutical, dietary, hygiene, and cosmetic products in dry, liquid and pasty forms.
12GF Score

Get the complete analysis for XTUN:SIPHA

5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

TND4.99
Price